Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer
Authors
Kopetz, SGrothey, A
Yaeger, R
Van, CE
Desai, J
Yoshino, T
Wasan, H
Ciardiello, F
Loupakis, F
Hong, YS
Steeghs, N
Guren, TK
Arkenau, HT
Garcia-Alfonso, P
Pfeiffer, P
Orlov, S
Lonardi, S
Elez, E
Kim, TW
Schellens, JHM
Guo, C
Krishnan, A
Dekervel, J
Morris, V
Calvo, FA
Tarpgaard, LS
Braun, Michael S
Gollerkeri, A
Keir, C
Maharry, K
Pickard, M
Christy-Bittel, J
Anderson, L
Sandor, V
Tabernero, J
Affiliation
University of Texas M.D. Anderson Cancer Center, HoustonIssue Date
2019
Metadata
Show full item recordCitation
Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381(17):1632-43.Journal
New England Journal of MedicineDOI
10.1056/NEJMoa1908075PubMed ID
31566309Additional Links
https://dx.doi.org/10.1056/NEJMoa1908075Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa1908075
Scopus Count
Collections
Related articles
- Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.
- Authors: Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J
- Issue date: 2019 Jun 10
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
- Authors: Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT
- Issue date: 2018 Oct
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
- Authors: Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT
- Issue date: 2018 May
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
- Authors: Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S
- Issue date: 2021 Feb 1
- A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i>-Mutant Colorectal Cancer.
- Authors: van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM
- Issue date: 2017 Jun